Renal medullary carcinoma is a rare and aggressive kidney cancer that often affects teenagers and young adults, especially those with sickle cell trait. Early symptoms of renal medullary carcinoma can include blood in the urine, pain in the side or back, weight loss, and tiredness. It usually grows quickly, and many people with renal medullary carcinoma already have spread outside the kidney when it is found. Not everyone will have the same experience. Treatment often includes chemotherapy and supportive care, and surgery may help in selected cases, but renal medullary carcinoma can be life-threatening.
How many people live with Renal medullary carcinoma?
There is no widely accepted, up-to-date estimate for how many people are living with renal medullary carcinoma worldwide or in the United States. It is an ultra-rare form of kidney cancer, and published medical sources usually report only scattered case reports and small case series rather than a reliable current count.
Overview
Renal medullary carcinomaSymptoms
Renal medullary carcinoma often causes blood in the urine and pain in the side or lower back. Many also develop tiredness, weight loss, or fever. Early symptoms of renal medullary carcinoma can be easy to miss.
Outlook and prognosis
Renal medullary carcinoma often grows quickly, so outlook is usually serious, especially if it has already spread when found. Still, some people live longer with prompt specialist care, newer drug treatments, and strong support for symptoms and daily life.
Causes and risk factors
Renal medullary carcinoma is strongly linked to sickle cell trait, and less often sickle cell disease. It mostly affects younger people of African ancestry; the exact cause is unclear, but inherited blood-cell changes are the main risk factor.
Genetic influences
Genetics are very important in renal medullary carcinoma. It is strongly linked to sickle cell trait or, less often, sickle cell disease, and tumor cells usually lose a gene called SMARCB1, a key genetic change.
Diagnosis
Renal medullary carcinoma is diagnosed with imaging tests such as CT or MRI, then confirmed by a biopsy. Doctors also use urine, blood, and sickle cell trait testing to help guide the diagnosis.
Treatment and drugs
Treatment for renal medullary carcinoma often combines chemotherapy and medicines that target the cancer, and surgery may help in selected cases. Many also need strong pain control, fluids, and care for sickle cell trait or disease-related complications.
Symptoms
Renal medullary carcinoma can show up as blood in the urine, pain in the side or lower back, unusual tiredness, and weight loss that was not planned. Because this cancer often grows quickly, some people first notice that normal activities like walking across campus or getting through a workday suddenly feel harder. Symptoms vary from person to person and can change over time. In some cases, the early symptoms of renal medullary carcinoma do not appear until the cancer has already spread.
Blood may make urine look pink, red, or cola-colored, but sometimes it is only found on a urine test. In renal medullary carcinoma, this can come and go rather than happen every time you urinate.
Pain often shows up on one side between the ribs and hip or in the lower back. It may begin as a dull ache and become more constant or sharper over time.
Some people feel discomfort, fullness, or pressure in the abdomen. A growing kidney tumor can make bending, sitting for long periods, or wearing tighter clothing feel uncomfortable.
Many living with renal medullary carcinoma feel unusually tired, weak, or short of breath with activity. This can happen because of the cancer itself or because ongoing blood loss can lead to anemia, meaning a low red blood cell count.
How people usually first notice Renal medullary carcinoma?
Renal medullary carcinoma is often first noticed when a young person, often someone with sickle cell trait, develops blood in the urine, which can be alarming because it may come and go at first. Many people with renal medullary carcinoma also begin to feel persistent pain in the side or lower back, and some notice fatigue, weight loss, or a lump in the abdomen as the cancer grows. Because these early warning signs can look like more common kidney or urinary problems, they are easy to brush off, so ongoing blood in the urine or unexplained flank pain should be checked promptly.
Types of Renal medullary carcinoma
There are no widely recognized types of renal medullary carcinoma in routine care. Instead, doctors usually describe renal medullary carcinoma by how far it has spread and which symptoms stand out. Sometimes, symptoms cluster together in recognizable ways. Early symptoms of renal medullary carcinoma often involve the urinary tract, while more advanced disease can cause broader whole-body problems.
Localized disease
When renal medullary carcinoma is still mainly in the kidney, blood in the urine and pain in the side or lower back are often the first signs. Some people also notice a mass, ongoing discomfort on one side, or unexplained weight loss.
Metastatic disease
When the cancer has spread beyond the kidney, symptoms often become more general and more intense. Many living with renal medullary carcinoma may have fatigue, ongoing weight loss, shortness of breath, bone pain, or swelling depending on where the cancer has traveled.
Urinary symptoms
Some people with renal medullary carcinoma mainly notice changes linked to the urinary system. These can include visible blood in the urine, pain with urination, needing to urinate more often, or trouble passing urine if the tumor blocks flow.
Whole-body symptoms
In other people, the main problem is not urinary symptoms but a steady decline in how they feel day to day. Fever, night sweats, low energy, poor appetite, and fast weight loss can all happen, especially when renal medullary carcinoma is advanced.
Can I slow down the onset of symptoms?
Right now, there is no good evidence that lifestyle changes or medicines can meaningfully delay the start of symptoms in renal medullary carcinoma, a rare, fast-growing kidney cancer. Healthy habits like not smoking and keeping up with routine medical care are still good for overall health, but they have not been shown to prevent this cancer or push back when it begins; research is ongoing, especially because this cancer is strongly linked to sickle cell trait. There is also no well-established screening test or preventive medicine for people at risk, so the most helpful step is to get checked quickly for warning signs like blood in the urine, pain in the side, or unexplained weight loss, which can help people start care sooner without guaranteeing a different outcome.
What genetics can tell you about symptoms
Genetics can give some clues about symptoms in renal medullary carcinoma, but it usually does not predict exactly what someone will feel day to day. This cancer is strongly linked to having sickle cell trait or, less often, sickle cell disease, and changes in the tumor itself can affect how aggressive it is, which may influence how quickly symptoms such as blood in the urine, pain, weight loss, or tiredness appear and how severe they become. Even so, symptoms can vary a lot from one person to another, so genetic findings are only one part of the picture.
Causes and risk factors
Renal medullary carcinoma most often develops in people with sickle cell trait. This trait is more common in people of African ancestry, and the cancer is also seen more often in teens, young adults, and males. The inherited blood change seems to raise risk because the inner part of the kidney often has low oxygen, which can stress cells over time. Doctors often find loss of a tumor-control gene called SMARCB1 in the cancer cells. Having sickle cell trait does not mean you will definitely develop renal medullary carcinoma, and no clear lifestyle or environmental risk factors for renal medullary carcinoma have been proven.
What are the most common causes or risk factors?
The strongest known risk factor for renal medullary carcinoma is being born with sickle cell trait, and it can also happen in people living with sickle cell disease or other inherited blood conditions related to sickle hemoglobin. It is seen most often in teens and young adults and is somewhat more common in males, but these are patterns rather than proven causes. Unlike many other cancers, there are no well-established lifestyle or environmental causes, such as diet or smoking, that have been clearly linked to this cancer.
Environmental and biological risk factors
When people ask about risk factors for renal medullary carcinoma, the answer is usually more about internal biology than outside exposure. Doctors often group risks into internal (biological) and external (environmental). For this rare kidney cancer, the strongest link is with sickle cell trait or sickle cell disease, while age and sex also seem to matter. No outside exposure has been proven to be a major cause.
Having sickle cell trait, and less often sickle cell disease, is the strongest known risk factor for renal medullary carcinoma. These blood conditions can cause repeated low-oxygen stress in the inner part of the kidney, where this cancer begins.
This cancer is seen most often in teenagers and young adults, although it can occur later in life. Many people living with renal medullary carcinoma are diagnosed before age 40.
Renal medullary carcinoma has been reported more often in males than in females. Sex alone does not cause the cancer, but it appears to influence overall risk.
Renal medullary carcinoma is diagnosed more often in people of African ancestry. This is thought to mainly reflect the higher rate of sickle cell trait in these populations, rather than ancestry being a direct cause by itself.
Genetic risk factors
This rare kidney cancer is most often linked to an inherited blood-cell trait called sickle cell trait, and less often to other sickle hemoglobin disorders. In renal medullary carcinoma, the key inherited risk usually begins with a change in the HBB gene, which affects hemoglobin, the protein that carries oxygen in red blood cells. Carrying a genetic change doesn’t guarantee the condition will appear. Knowing this link can help doctors take early symptoms of renal medullary carcinoma seriously, especially blood in the urine or pain in one side of the back.
Sickle cell trait: This is the strongest inherited risk factor for renal medullary carcinoma. Most people with sickle cell trait never develop this cancer, but the link is strong enough that doctors routinely look for it.
Other sickle disorders: This cancer can also occur in people living with sickle cell disease or related sickle hemoglobin disorders. These conditions are much less common than sickle cell trait, so fewer cases are seen, but they still matter for risk.
HBB gene change: The inherited change behind sickle cell trait and sickle cell disease sits in a gene called HBB. This gene affects hemoglobin and seems to create the setting in which the cancer can develop.
SMARCB1 loss: In renal medullary carcinoma, a gene called SMARCB1 is usually missing or switched off in the tumor cells. This change is usually acquired in the cancer itself rather than inherited from a parent.
Family history: Most cases are not part of a strong inherited family cancer syndrome. If sickle cell trait or sickle cell disease runs in a family, relatives may share that blood-cell gene change, but that does not mean cancer is expected.
Lifestyle risk factors
For renal medullary carcinoma, lifestyle factors are not considered the main cause, and most cases are linked to underlying biology rather than personal habits. Still, how lifestyle affects renal medullary carcinoma can matter for kidney stress, symptoms, and how well someone tolerates treatment. Evidence is limited because this cancer is rare, so these points are best viewed as factors that may influence progression, complications, or overall health rather than proven direct causes.
Tobacco use can worsen blood vessel injury and kidney stress, which may add strain in a cancer that already affects the kidney. Smoking is also linked to poorer surgical recovery and reduced tolerance of some cancer treatments.
Chronic dehydration may increase medullary stress in the kidney, an area already central to renal medullary carcinoma. Good hydration does not prevent the cancer, but it may help reduce additional kidney strain and support overall function during treatment.
Poor lifestyle habits that raise blood pressure, such as excess salt intake, inactivity, and heavy alcohol use, can further damage kidney tissue. In someone with renal medullary carcinoma, that added kidney injury may complicate symptoms, treatment planning, and preservation of remaining kidney function.
A diet high in ultra-processed foods and low in fruits, vegetables, and adequate protein can worsen general health and make treatment recovery harder. Good nutrition does not cure renal medullary carcinoma, but it can help maintain strength, body weight, and resilience during intensive care.
Risk prevention
Renal medullary carcinoma is a rare kidney cancer, and there is no proven way to fully prevent it. For many, prevention is really about lowering risk where possible and finding the cancer early, especially in people with sickle cell trait or sickle cell disease. Prevention is about lowering risk, not eliminating it completely.
Most cases of renal medullary carcinoma happen in people with sickle cell trait, and less often in people with sickle cell disease. If you or family members know this runs in your background, sharing that history with your doctor can help them take blood in the urine or ongoing side pain more seriously.
Repeated dehydration may add stress to the kidney, which is especially important for people at higher risk of renal medullary carcinoma. Drinking enough fluids during daily life, illness, sports, or hot weather may help reduce that strain.
Extreme heat and heavy exertion can raise the chance of dehydration and other sickle cell-related stress on the body. Taking breaks, cooling down, and replacing fluids during exercise or physically demanding work are sensible precautions.
Smoking is linked to kidney and urinary tract cancers in general, even though its exact role in renal medullary carcinoma is not fully clear. Avoiding tobacco and secondhand smoke is a practical way to lower overall kidney cancer risk.
Can you prevent Renal medullary carcinoma?
Renal medullary carcinoma usually cannot be prevented. Because it is strongly linked to sickle cell trait or sickle cell disease, there is no known way to fully stop it from developing. If you have one of these blood conditions, staying in regular medical care and getting warning signs like blood in the urine or side pain checked quickly may help find problems earlier, but this has not been proven to prevent the cancer itself.
Transmission
Renal medullary carcinoma is not infectious, so it cannot be caught from someone through air, touch, sex, food, or blood. For many living with this cancer, the more important question is how renal medullary carcinoma is inherited, and the answer is that the cancer itself is usually not passed directly from parent to child.
What can run in families is sickle cell trait, or less often sickle cell disease, which is strongly linked to renal medullary carcinoma and raises the chance that it may develop. In most cases, the cancer forms because gene changes happen later in the kidney cells themselves, so even if a relative has renal medullary carcinoma, that does not usually mean others in the family will get it.
When to test your genes
There is no routine inherited gene test to screen for renal medullary carcinoma early. If you have this cancer, or a kidney mass plus blood in the urine and sickle cell trait or sickle cell disease is possible, ask about testing for hemoglobin status and tumor genetics, especially SMARCB1 loss, to confirm the diagnosis and guide care.
Diagnosis
Renal medullary carcinoma is usually diagnosed after symptoms such as blood in the urine, side or back pain, weight loss, or tiredness lead to testing. Because this cancer is rare and can look like other kidney problems at first, the diagnosis of renal medullary carcinoma often involves several exams done close together. It’s natural to worry when symptoms don’t have a clear explanation.
Doctors usually begin by asking about symptoms, how long they have been happening, and whether there is a history of sickle cell trait or sickle cell disease. A physical exam can help look for tenderness, a mass, or signs that the illness is affecting the rest of the body.
Urine tests may show blood or other changes that suggest bleeding or irritation in the urinary tract. Blood tests check kidney function, anemia, and general health, and other lab tests may help rule out common conditions.
Imaging scans of the kidneys and abdomen are central to how renal medullary carcinoma is diagnosed. A contrast CT scan is often used first, while MRI may help if more detail is needed or if contrast dye is not suitable.
Because renal medullary carcinoma can spread early, doctors often order a chest CT scan or chest X-ray. This helps check whether the lungs or nearby lymph nodes may be involved.
How is Renal medullary carcinoma diagnosed?
Renal medullary carcinoma is usually first suspected when imaging tests such as a CT scan or MRI show a kidney mass, often in someone who has blood in the urine, pain in the side, or unexplained weight loss. The diagnosis is confirmed by taking a small sample of the tumor with a needle or during surgery and examining it under a microscope, sometimes with extra lab tests to tell it apart from other kidney cancers. Doctors also often do a blood test for sickle cell trait or sickle cell disease, because this cancer is strongly linked to those conditions.
Stages of Renal medullary carcinoma
Renal medullary carcinoma does not have defined progression stages. This is because it is usually identified by how advanced the cancer is at the time of diagnosis, rather than by a clear set of step-by-step phases that everyone moves through. Often the process begins when you notice changes in daily life, such as blood in the urine, ongoing side pain, or tiredness, and doctors then use scans, urine and blood tests, and a tissue sample called a biopsy to confirm the diagnosis. Because the early symptoms of renal medullary carcinoma can overlap with other kidney problems, follow-up usually focuses on imaging results, biopsy findings, and how far the cancer has spread.
Outlook and prognosis
Renal medullary carcinoma generally has a poor prognosis because it is highly aggressive and is often diagnosed at an advanced or metastatic stage. In many reported series, median overall survival has been measured in months rather than years, commonly around 6 to 13 months, although outcomes vary with stage, performance status, and response to therapy. Survival is better when the tumor is found early enough for complete surgical removal, but this is uncommon. Even with multimodality treatment, including platinum-based chemotherapy and sometimes surgery or newer targeted or immunotherapy approaches, relapse and progression are frequent. Mortality is high, and metastatic disease is associated with particularly short survival. Ongoing advances in specialized cancer care may improve outcomes for some patients, but long-term survival remains rare.
Long-term effects
Renal medullary carcinoma often affects day-to-day life because it tends to grow quickly and is frequently advanced by the time it is found. Long-term effects can come from the cancer itself, especially if it spreads, and from treatment such as surgery, chemotherapy, or immunotherapy. The long-term picture is often shaped by how far the cancer has spread and how well it responds to treatment. Even when the early symptoms of renal medullary carcinoma seemed limited at first, the condition can still have serious long-term effects.
Renal medullary carcinoma often spreads to places like the lungs, liver, lymph nodes, or bones. This can lead to ongoing shortness of breath, bone pain, swelling, or other organ-related problems over time.
Many people with renal medullary carcinoma lose kidney function from the tumor itself or after surgery to remove part or all of a kidney. If both kidneys are affected or the remaining kidney is not working well, long-term kidney disease can develop.
Pain in the side, back, or bones can become an ongoing issue, especially when the cancer has spread. For many, symptoms may rise and fall over time and can affect sleep, movement, and daily routines.
Ongoing tiredness, weakness, and unintentional weight loss are common long-term effects of advanced renal medullary carcinoma. These problems may come from the cancer, reduced appetite, anemia, or the strain of treatment.
How is it to live with Renal medullary carcinoma?
Living with renal medullary carcinoma can feel like life changes all at once, because this is a rare and aggressive kidney cancer that often brings pain, blood in the urine, fatigue, weight loss, and frequent medical visits in a short span of time. For many people, daily life quickly starts revolving around scans, appointments, treatment decisions, and managing symptoms, which can make work, school, sleep, and ordinary routines much harder. The impact often reaches beyond the person with cancer too, as family and friends may take on caregiving, transportation, financial stress, and the emotional weight of uncertainty, so practical support and honest communication can make a real difference.
Treatment and drugs
Renal medullary carcinoma is usually treated with a combination of approaches, because this is a rare, aggressive kidney cancer that often needs fast, specialist care. Treatment often looks different for each person, but it commonly includes chemotherapy, and some people may also have surgery if the tumor can be removed safely. If the cancer has spread or comes back, doctors may consider newer drug options such as immunotherapy or targeted treatment, although response can vary and clinical trials may also be discussed. Alongside medical treatment, care often includes help with pain, fatigue, nutrition, and other day-to-day symptoms, since supportive care can make a real difference in how you feel. Because early symptoms of renal medullary carcinoma can be easy to miss and the disease can move quickly, care is usually best planned by a team with experience in kidney cancer.
Can you cure Renal medullary carcinoma?
Renal medullary carcinoma is a rare, fast-growing kidney cancer, and in most cases there is no cure, especially if it has already spread. If it is found very early, surgery to remove the kidney may sometimes offer the best chance of long-term control, but this is uncommon. Treatments such as chemotherapy, symptom relief, and sometimes clinical trials can help shrink the cancer, ease symptoms, and may help people live longer.
Non-drug treatment
Daily life with renal medullary carcinoma can change quickly, so non-drug care often focuses on both controlling the cancer and helping you feel as well as possible during treatment. Depending on how far the cancer has spread, this may include surgery, radiation, and procedures to relieve blockage or bleeding. Supportive therapies can also ease pain, fatigue, appetite loss, and the emotional strain that often comes with an aggressive cancer. Not every approach works the same way, and the plan is usually tailored to your symptoms, scan results, and overall health.
Surgery for renal medullary carcinoma may be an option when the tumor is mainly in one kidney or when doctors think removing it could help with symptoms and overall treatment. This often means removing the affected kidney, and sometimes nearby tissue or lymph nodes as well. Because this cancer is often advanced at diagnosis, surgery is not the right fit for everyone.
Radiation uses targeted high-energy beams to shrink areas of cancer and relieve symptoms such as pain, bleeding, or pressure. It is often used when the cancer has spread to bones, the spine, or other specific sites. For many, treatment begins not at the pharmacy, but in short outpatient visits over days or weeks.
If the tumor blocks urine flow, doctors may place a ureteral stent or a nephrostomy tube to help the kidney drain. These procedures can reduce pain, protect kidney function, and lower the risk of infection. They may also help if swelling in the kidney is adding to discomfort.
Palliative care focuses on symptom relief, comfort, and day-to-day function at any stage of renal medullary carcinoma, not only near the end of life. This kind of care can help with pain, nausea, shortness of breath, sleep problems, and difficult treatment decisions. Many living with renal medullary carcinoma receive palliative care alongside cancer-directed treatment.
Your genes may have an impact on how drugs work for you
For people living with renal medullary carcinoma, there is not yet a well-established, routine gene test that can reliably tell doctors which common cancer medicines will work best or cause more side effects. In some cases, doctors may study changes in the tumor itself to look for treatment options or research studies that could be a better fit, but this is different from using an inherited gene test to predict day-to-day drug response. Because this cancer is rare and can behave differently from one person to another, treatment choices are usually guided more by the cancer’s features, past response to treatment, and overall health than by standard drug-response genetic testing.
Pharmacological treatments
Because renal medullary carcinoma often grows quickly, treatment usually needs to start soon after diagnosis and most often relies on medicines that circulate through the bloodstream. In renal medullary carcinoma, the main drug treatment is combination chemotherapy, especially platinum-based regimens. First-line medications are those doctors usually try first, based on the best evidence available, and for this cancer that usually means cisplatin or carboplatin with gemcitabine, sometimes with paclitaxel. Immunotherapy or other newer drugs may be considered for selected people, often through a cancer center with experience in rare kidney tumors or in a clinical trial.
Cisplatin or carboplatin, usually paired with gemcitabine, is the most commonly used drug treatment for renal medullary carcinoma. This is often the first-line treatment for renal medullary carcinoma because these medicines can shrink or slow the cancer, although the response may not last.
Gemcitabine is often combined with a platinum drug and is a key part of many treatment plans. It is given by vein, usually in repeated cycles, and doctors monitor blood counts and kidney function during treatment.
Paclitaxel may be added to cisplatin, carboplatin, or gemcitabine in some cases, especially when doctors want a stronger multi-drug approach. Not everyone responds to the same medication in the same way, so the exact combination is tailored to overall health and how the cancer is behaving.
Checkpoint inhibitors such as pembrolizumab or nivolumab, sometimes with ipilimumab, may be used for some people with advanced renal medullary carcinoma. These medicines help the immune system recognize and attack cancer cells, but they are not yet a proven standard for everyone with this tumor.
Genetic influences
For many living with sickle cell trait, hearing about renal medullary carcinoma can raise urgent questions about inherited risk. In this cancer, genetics matter in a very specific way: renal medullary carcinoma develops almost only in people who inherited a sickle hemoglobin change, most often sickle cell trait and less often sickle cell disease. Having a genetic risk is not the same as having the disease itself, and renal medullary carcinoma is still very rare even among people with sickle cell trait. Inside the tumor, doctors also usually find loss of a gene called SMARCB1, which normally helps keep cell growth under control, but this change is usually acquired in the cancer cells rather than passed down through a family. This helps explain the genetic causes of renal medullary carcinoma: an inherited sickle hemoglobin change appears to create the setting for the cancer, while additional gene damage in the kidney cells helps the tumor form. In most cases, family history of kidney cancer is not the main clue, but a history of sickle trait, sickle cell disease, or related blood conditions can be important.
Is Renal medullary carcinoma genetic?
Genetics are very important in renal medullary carcinoma. It is strongly linked to sickle cell trait or, less often, sickle cell disease, and tumor cells usually lose a gene called SMARCB1, a key genetic change.
Having a genetic risk is not necessarily a diagnosis
Gene variants are a normal part of human biology and are common across the general population. Most of these variants do not directly affect health and simply reflect natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when more than one gene and environmental factors are involved. In some situations, though, one well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with renal medullary carcinoma, treatment decisions are shaped by the tumor’s genetics as much as by scans or biopsy results. Doctors often check for loss of a gene called SMARCB1, also known as INI1, because this change is a hallmark of renal medullary carcinoma and helps confirm the diagnosis. The cancer is also closely linked to sickle cell trait or sickle cell disease, which matters for overall care, but it does not usually point to one proven drug the way some other cancers do.
Beyond trial and error, genetics offers another way to look for treatment options when standard chemotherapy is not enough. Right now, there is no widely used pharmacogenetic test that reliably tells doctors which common renal medullary carcinoma drug will work best or cause fewer side effects for one specific person. Still, genetic testing for renal medullary carcinoma treatment may uncover rare changes that open the door to a clinical trial or a targeted medicine, and it can help specialists match care more closely to the cancer’s biology.
Interactions with other conditions
Renal medullary carcinoma often appears in people who also carry sickle cell trait, and less often sickle cell disease, so symptoms such as blood in the urine, side pain, or tiredness can at first be mistaken for problems related to sickling rather than a kidney cancer. Having more than one diagnosis can make symptoms feel harder to untangle. As renal medullary carcinoma grows, it can also worsen kidney function, which may complicate other conditions such as high blood pressure, anemia, or chronic kidney disease and make day-to-day health harder to manage. Many living with renal medullary carcinoma are also at risk of blood clots, infections, or severe pain, especially during treatment, and these problems can interact with other illnesses and affect which medicines are safest. Because renal medullary carcinoma is aggressive, doctors usually look closely at the whole picture, including sickle cell status, kidney health, and any other active medical problems, before choosing treatment. If you are facing renal medullary carcinoma along with another condition, coordinated care between cancer, kidney, and blood specialists can help reduce treatment conflicts and better control symptoms.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Renal medullary carcinoma?
Kidney stones, urinary tract or kidney infections, and other types of kidney cancer can all cause similar signs, especially blood in the urine and pain in the side or back. Cancer in the lining of the urinary tract, including the bladder or the tube that drains the kidney, can also look similar at first. In people with sickle cell trait, some kidney problems linked to that trait may be mistaken for renal medullary carcinoma until scans and a tissue sample make the cause clear.
History
For many people living with renal medullary carcinoma, the story often begins with symptoms that can look like more common kidney problems, such as blood in the urine, side or back pain, or unexplained weight loss. That helps explain why this cancer was not clearly recognized until fairly recently, even though doctors had long seen rare, aggressive kidney tumors in younger people, especially those with sickle cell trait.
In the 1990s, pathologists began describing renal medullary carcinoma as a distinct type of kidney cancer rather than grouping it with other tumors. In recent decades, awareness has grown as doctors learned that its pattern, age group, and link with sickle cell trait made it different from the more common kidney cancers seen in older adults. This mattered because the early symptoms of renal medullary carcinoma can overlap with infections, kidney stones, or other urinary problems, which sometimes delayed diagnosis.
As more cases were reported, researchers built a clearer picture of how this cancer behaves. They found that renal medullary carcinoma often grows quickly and is frequently advanced by the time it is discovered. Improvements in imaging, pathology, and cancer classification helped doctors recognize it more reliably, while later laboratory research showed that it has a distinct biological basis rather than being just a variation of another kidney cancer.
The history of renal medullary carcinoma is short compared with many other cancers, but it has changed medical care in important ways. Earlier recognition has helped doctors know when to consider this diagnosis in someone with concerning kidney symptoms and sickle cell trait or a related sickling condition. Even so, because renal medullary carcinoma is rare and aggressive, it remains an active area of research, with ongoing efforts to improve diagnosis, treatment, and outcomes.